Rash relief? antifungal drug shows promise for cancer treatment side effect

NCT ID NCT03471364

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested whether ketoconazole, an antifungal drug, can reduce the skin rash caused by EGFR inhibitor cancer therapy. 58 participants with ongoing rash were given either ketoconazole or a placebo. The main goal was to see if the drug improved rash symptoms and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Carle Cancer Center

    Urbana, Illinois, 61801, United States

  • Carle on Vermilion

    Danville, Illinois, 61832, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Park Nicollet Frauenshuh Cancer Center

    Saint Louis Park, Minnesota, 55426, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • University of Rochester

    Rochester, New York, 14642, United States